BUZZ-Morgan Stanley starts Certara at 'equal weight'
Reuters
Jul 03, 2025
BUZZ-<a href="https://laohu8.com/S/MTK">Morgan Stanley</a> starts Certara at 'equal weight'
** Morgan Stanley initiates coverage of drug development software provider Certara CERT.O with an "equal weight" rating
** "A key focus for the company is biosimulation, where Certara's platforms are designed to optimize drug design and testing" - Brokerage
** Morgan Stanley says CERT has a market-leading platform and generates strong recurring revenues with significant cross-selling opportunities
** Brokerage PT remains unchanged at $16, a ~39.3% upside on the stock's last close
** Five of 11 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $16 - LSEG data
** As of last close, stock up ~7.9% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.